The aim of the current study was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium in patients with severe mitral valve regurgitation (MR) during the anaesthetic induction period.
Introduction
Cisatracurium besilate (NIMBEX, 51 W89) is often used in anaesthesia as a nondepolarizing neuromuscular blocking agent [3] . The R-cis, R'-cis isomer of atracurium besilate is also used as a nondepolarizing neuromuscular blocking agent [4] . Compared with atracurium, cisatracurium is approximately three times more potent and has a lower propensity to cause histamine release [5] . It is frequently used as a muscle relaxant to facilitate endotracheal intubation during elective surgery [6] . It is also utilized in the management of critically ill patients in intensive care units [4] . This agent undergoes spontaneous temperature-and pH-dependent chemical (Hofmann) degradation in the plasma and tissues [7] . This degradation is the major route (about 77%) of its total clearance in vivo [8] . The pharmacological activity of the major metabolites of cisatracurium (e.g. laudanosine, tetrahydropapaverine and a monoquaternary acrylate) has not been elucidated [9] .
Mitral valve regurgitation (MR), also called mitral valve insufficiency, is a disorder in which the mitral valve of the heart does not close properly, allowing blood to flow backwards into the heart [10] . Consequently, the blood is unable to move through the heart or to the rest of the body as efficiently, making patients feel tired or out of breath [10] . MR is one of the most common types of heart valve disorder [11] . Severe MR is a condition in which the effective regurgitant orifice area reaches 0.2 cm 2 and the regurgitant volume can be as high as 30 ml, according to the American Heart Association and the American College of Cardiology [12] . For patients with severe MR, surgery is the optimal treatment due to its well-documented advantages over medications in terms of preservation of postoperative left ventricle function and long-term survival [13] . Due to its extremely low cardiovascular effect, cisatracurium is frequently used for the purpose of promoting endotracheal intubation in patients with severe MR during the surgical period [9, 14, 15] . However, the pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium in patients with severe MR remain unknown, which could undermine its rational administration and safe clinical therapy. It is therefore necessary to determine the PK and PD properties of cisatracurium in patients with severe MR. A total of 30 patients were selected for the clinical trial and divided into two groups (i.e. control and MR groups). Blood samples were collected before (time 0) and at 1, 2, 4, 8, 12, 15 and 20 min after cisatracurium administration. The neuromuscular block effect was monitored by train-of-four (TOF) testing. A conventional two-compartment model and integrated PK/PD model were applied to PK and PD data analysis, respectively.
Methods

Subjects
The protocol (No. GDREC2015297H) was approved by the Guangdong General Hospital Ethics Committee ( Figure S1 ). The registration number was ChiCTR-OOC-15 007 231. Written informed consent was given by the patients before the clinical trial. A total of 30 patients were included in the study and divided into two groups: the MR group (n = 15) and control group (n = 15). Patients in the MR group suffered from severe MR. Patients who had been diagnosed with inguinal hernia but had intact cardiac structure and normal heart function were selected as control patients. Several criteria for the selection of patients were applied to both groups, including: (i) age 20-55 years old; (ii) body mass index (BMI) 20-24 kg m À2 ; (iii) American Society of Anesthesiologists physical status I or II; (iv) diagnosis of severe mitral regurgitation (regurgitation fraction >60%); (v) the drugs used before surgery did not include neuromuscular stimulants; and (vi) no allergies to muscle relaxants. Patients were excluded if they showed any evidence of clinically significant pulmonary, psychiatric, neuromuscular or neurological disease, as well as significant renal or liver impairment.
Preparation before anaesthesia
Demographic information (e.g. age, gender, height and weight) was collected for each patient. Blood cell counts, liver function and renal function were measured by routine laboratory tests. Patients were not allowed to eat for eight hours and drink for four hours before surgery. About 1 ml blank blood was collected for blood gas analysis in a blood gas analyser (IRMA TruPoint; LifeHealth, LLC, Roseville, MN, USA). 
Anaesthetic experimental design
Neuromuscular monitoring
The TOF testing was performed to measure the degree of neuromuscular blockade of cisatracurium using a peripheral nerve stimulator in TOF-Watch SX (Organon, Ireland). This was performed by measuring the magnitude of the first twitch (T1) elicited through electrodes placed approximately 2-3 cm apart along the ulnar nerve path. The stimuli to the ulnar nerve were delivered as a group of 0.2 ms pulses, spaced 500 ms ±5% apart (at a rate of 2 Hz). This pattern was repeated every 15 s. A stabilization period in which the tension of T1 in the TOF did not change (baseline value) was allowed before the administration of cisatracurium. The percentage of neuromuscular block was calculated by the ratio of the observed T1 value to the baseline value. The onset time was defined as the time to reach the maximum block.
Blood sampling
Arterial blood samples (about 4 ml) were obtained before (time 0) and at 1, 2, 4, 6, 8, 10, 15 and 20 min after intravenous injection of 0.15 mg kg À1 cisatracurium. Blood samples were immediately transferred to centrifuge tubes containing heparin and centrifuged (4°C) at 8000 g for 4 min. Plasma was collected and immediately mixed with 100 μl H 2 SO 4 (1 mM). The plasma samples were stored at À80°C until analysis. Plasma samples (200 μl) were deproteinized using acetonitrile (1000 μl). The resulting mixture was vortexed for 2 min, followed by centrifugation at 15 000 g for 15 min (4°C). The supernatant was collected and dried using Eppendorf Concentrator Plus (Hamburg, Germany). The residue was reconstituted in a solution of water/acetonitrile (50:50, v/v; 200 μl) and centrifuged at 15 000 g for 15 min (4°C). A 25 μl aliquot of the supernatant was injected into the high-performance liquid chromatography (HPLC) system for cisatracurium quantification.
HPLC analysis
The concentration of cisatracurium in the plasma was determined by the Dionex Ultimate 3000 series HPLC system (Thermo Scientific, MA, Philadelphia, USA), consisting of a quaternary pump, a degasser, an autosampler, a column heater and a multichannel rapid scanning ultraviolet-visible spectroscopy detector. Chromatographic separation was performed on a C18 column (Acclaim 120 C18, 5 m, 4.6 mm × 200 mm, Thermo Scientific) maintained at 40°C. Elution was performed using water (mobile phase A) vs. acetonitrile (mobile phase B) at a flow rate of 1 ml min À1 . The elution gradient was 30-50% B at 0-9 min, 85% B at 9-10 min and 50-30% B at 10-12 min. The injection volume was set to 25 μl and the detection wavelength was 283 nm.
Method validation
The linearity of the standard curve was determined by a 1/x 2 weighted linear least-squares regression method. The limit of quantification (LOQ) was defined as the final compound concentration producing a signal-to-noise ratio larger than 10. Accuracy was measured as the percentage deviation of the mean detected concentrations from the nominal concentrations. Precisions were determined by evaluating the measured results of cisatracurium at low, medium and high concentrations. The equation for precision was shown below:
Precision ¼ standard deviation of measured concentration mean of measured concentration Â100%
PK/PD analysis
The PK data for cisatracurium were analysed using a conventional two-compartment model. The effect compartment, representing the site of drug action, was added to the central compartment of the two-compartment model by a first-order process, to construct a PK/PD model for the PD analysis ( Figure 1 ). The PD data were described by a sigmoid E max model:
where E max was the drug-induced maximal effect, EC 50 was the concentration required to produce half of the druginduced maximal effect, γ was the slope factor and C e was the drug concentration in the effect compartment. Model construction and parameter estimation were performed using WinNonlin software (Pharmsight, Mountain View, CA, USA). PK/PD analysis was performed following a standard twostage procedure. Firstly, PK data alone were fitted to PK model, to obtain PK parameters. Secondly, PD data analysis was performed using the PK/PD link model to obtain PD parameters. In the second step, PK parameters in the PK/PD model were fixed at those corresponding values derived from the first step.
Statistical analysis
Data were presented as mean ± standard deviation (SD). The unpaired Student's t-test was used to analyse the significant differences in the PK and PD parameters between control and MR groups. The prior level of significance was set at 5% or P < 0.05.
Results
Study subjects
A total of 30 patients were divided into two groups (i.e. the control and MR groups) ( Table 1) . In order to exclude demographic influence, similar subjects were selected for the two groups with respect to age, gender, race and BMI ( Table 1) . As the main route of elimination for cisatracurium in vivo is pH-and temperature-dependent Hofmann degradation, pH and body temperature were also measured by blood gas analysis for all patients [8] . No significant differences were found in pH and body temperature values between the two groups (Table 2) . However, other parameters derived from the blood gas analysis -namely, the haemoglobin (Hb) level and haematocrit (Hct) -were significantly higher in patients with severe MR than in those in the control group (12-28%, P < 0.001; Table 2 ).
Quantification of plasma cisatracurium by HPLC
The concentration of cisatracurium in the plasma was determined effectively by the HPLC system used. The analytical method had good linearity (R 2 > 0.99) in the concentration range 100-3200 ng ml À1 for cisatracurium, and was rigorously validated with respect to accuracy (within 90-110%) and precision (relative standard deviation (RSD) <10%). The limit of quantification was estimated at 25 ng ml À1 .
Altered cisatracurium PK in patients with serve MR
Mean plasma concentration vs. time curves for the control and MR groups were compared ( Figure 2 ). These showed that mean plasma cisatracurium concentration was significantly higher (P < 0.01) at early time points (≤ 4 min) in the MR group than in the control group, indicating that severe MR led to an elevation in the plasma concentration of cisatracurium. All individual plasma cisatracurium concentration-time data were fitted to the conventional two-compartment model. The goodness of fit was justified by the diagnostic plots ( Figures S2 and S3) . The predicted values from the model were closest to the observed ones ( Figures S2 and S3) . Figure 2 A comparison of mean plasma concentration versus time profile between the control and mitral regurgitation (MR) groups. Solid lines represent predicted data from the two-compartment model. Statistically significant differences in the plasma concentration between the control and MR groups at specific time points are indicated by asterisks (**P < 0.01; ***P < 0.001)
The mean values for the PK parameters for the two groups are listed in Table 3 . Compared with the control group, a significant decrease in the intercompartmental transfer rate constants k 12 and k 21 (36-45%, P < 0.001), describing the rate of drug exchange between the central and peripheral compartments, was observed in MR group. Consistently, the distribution half-life was decreased significantly (74%, P < 0.001) in severe MR patients compared with control patients. The steady-state volume of distribution and the volume of the central compartment were decreased to the same extent, and with an identical P value. The area under the curve (AUC) was elevated in the MR group (27%, P < 0.01), consistent with the higher plasma concentration of cisatracurium (at ≤ 4 min) in the MR group than in the control group. Taken together, the differences in the model parameters between the two groups suggested that severe MR reduced the distribution rate of cisatracurium, resulting in higher concentrations of the drug in the plasma. By contrast, severe MR did not induce changes in other parameters, including the elimination rate constant (K 10 ), T 1/2β and clearance.
Altered cisatracurium PD in patients with severe MR
A comparison of mean neuromuscular block value vs. time profiles between control and MR groups is displayed in Figure 3 . Clearly, the PD effects of cisatracurium were delayed in the MR group compared with the control group (Figure 3) . The time to the maximal neuromuscular blocking effect was delayed by about 2 min (2.08 min in the control group vs. 4.12 min in the MR group) in patients with severe MR compared with control patients (Table 4) . The mean PD parameters for the two groups, derived from integrated PK/PD model analysis, are summarized in Table 4 . The first-order rate constant (K e0 ), describing the speed of drug transfer from the central compartment to the effect compartment, was markedly decreased (36%, P < 0.001) in patients with severe MR compared with control patients, indicating the slower distribution rate of cisatracurium from the blood to the effect compartment. In comparison, none of other parameters, including E max , EC 50 and γ, were changed by severe MR.
Discussion
In the present study, we performed the first analysis of the PK and PD of cisatracurium in patients with severe MR. The 2.08 ± 0.32 4.12 ± 0.47* Data are presented as mean ± standard deviation. Statistically significant differences between the control and mitral regurgitation (MR) groups are indicated (*P < 0.001). γ, slope factor; EC 50 , concentration required to produce half of the drug-induced maximal effect; E max , drug-induced maximal effect; K e0 , first-order rate constant for drug transfer a Onset time was measured experimentally Figure 3 A comparison of mean neuromuscular block effect versus time profile between the control and MR groups isolated PK analysis demonstrated that severe MR reduced the distribution rate of cisatracurium, resulting in higher concentrations of the drug in the plasma (Table 3 ). In addition, the result of PK/PD model fitting demonstrated that the slower transfer rate of cisatracurium from the central compartment (plasma) to the effect compartment (effect site) may be the primary factor in the delay in the neuromuscular blocking effect (Table 4) . Therefore, our study has contributed to an understanding of the delay in the onset time of cisatracurium and the improvement in clinical therapeutic safety in patients with severe MR. The PK data fitted well to the conventional twocompartment model, with the predicted values being close to the experimental values (Figure 2) . The conventional two-compartment model has previously been shown to well describe the plasma concentration vs. time data for cisatracurium [16, 17] . The current model fitting results suggested that severe MR caused poorer drug distribution, resulting in higher concentrations of the drug in the plasma. Generally speaking, only the drug in the bloodstream can be eliminated by the clearing organs. However, there was no change in K 10 and T 1/2β . This was supported by the fact that the main elimination route for cisatracurium in vivo is organ-independent Hofmann degradation [8] .
We acknowledge that the sampling schedule (0-20 min) for the PK study may have been too short, thereby limiting the scientific utility and significance of the present study. The sampling schedule was chosen as being approximately equal to one half-life of cisatracurium. A relatively short schedule was also chosen so as to reduce the influence of frequent blood collections on patients in the PK study. Nevertheless, blood samples were collected at eight time points in the distribution and elimination phases of the concentration--time curve, providing sufficient data for PK model fitting. Hence, we believe that it was unlikely that the sampling schedule limited the scientific utility and significance of the study.
Previous studies have confirmed that the neuromuscular blocking effect of cisatracurium is directly related to the drug concentration at the site of pharmacological activity (i.e. the neuromuscular junction) [18] . Therefore, an indirect PK/PD model that was specifically applied to detect hysteresis in the plasma concentration-effect relationship was appriopriate to describe the time course of effect for cisatracurium. Moreover, the same PK/PD model has been used successfully to determine the PK and PD properties of cisatracurium in the previous studies [16, 17] . In the PK/PD model, K e0 , which includes the transfer rate from the central compartment to the effect compartment, was the key factor for drug exposure at the effect site. Accordingly, the decrease in k e0 was the main cause of the significant delay in the time to the maximal neuromuscular blocking effect, from 2.08 min to 4.12 min, for cisatracurium in patients with severe MR compared with patients in the control group.
The reasons for the decrease in the distribution rate from the central (plasma) to peripheral compartment (effect site) in patients with severe MR are unknown. However, severe MR, in which blood flows backwards into the left atrium, can result in heart failure, resulting in a reduction in the forward flow of blood from the ventricle to the body, which deprives the organs of blood [10] . This reduction in the flow of blood was supported in the present study by the fact that the haematocrit and haemoglobin concentration were found to be increased in patients with MR (Table 2) [19, 20] . This increase compensates for the poor transfer of oxygen due to the reduced blood flow. Membrane permeability and blood perfusion rate are two key factors explaining the effect of drug exposure in tissues [21] . It is unlikely that severe MR can alter the membrane permeability of neuromuscular tissues. Furthermore, it has been well established for muscle relaxants that Ke0 is strongly correlated with cardiac output [22] . Therefore, it is reasonable to speculate that the haemodynamic changes found in the present study were the fundamental reason for the decrease in the distribution rate for the patients with severe MR.
Disease can alter PK and PD properties, highlighting that understanding PK/PD relationships in various disease states is important for the safety of anaesthesia [23] . Induction is the riskiest stage of anaesthesia [23] . Failing to perform endotracheal intubation at the peak of the muscle-relaxant effect will cause damage to the respiratory system and disturb the functioning of the anaesthetist, increasing the possibility of an anaesthetic accident [24] . In clinical practices, anaesthetists usually perform endotracheal intubation 2 min after the intravenous injection of 0.15 mg kg À1 cisatracurium [9] . However, based on the results of the present study, this would cause tissue damage to patients with severe MR undergoing elective surgery as it would delay the onset time of the neuromuscular blocking effect. We suggest that endotracheal intubation should be delayed until 4 min after the intravenous administration of 0.15 mg kg À1 cisatracurium in patients with severe MR.
In conclusion, we have determined, for the first time, the PK and PD characteristics of cisatracurium in patients with severe MR, using PK and integrated PK/PD model analysis. The PK model analysis demonstrated that severe MR reduced the distribution rate of cisatracurium, resulting in a higher concentration of the drug in the plasma. Moreover, the PK/PD model suggested that the slower rate of distribution of cisatracurium from the blood to the effect compartment might be the main cause of the PD delay. The present study has the potential to improve the safety of anaesthetic induction in patients with severe MR through the accurate prediction of the PD responses of cisatracurium using the established PK/PD model. 21 615 463, the code of department: 540 000; the name of unit: First Affiliated Hospital of Jinan University).
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